Targeted Therapy for Adult T Cell Leukemia/Lymphoma
Author Information
Author(s): Nasr Rihab, Hajj Hiba El, Kfoury Youmna, de Thé Hugues, Hermine Olivier, Bazarbachi Ali
Primary Institution: American University of Beirut
Hypothesis
Can the combination of zidovudine and interferon-alpha improve survival in ATL patients?
Conclusion
The combination of zidovudine and interferon-alpha significantly improves survival in patients with adult T cell leukemia/lymphoma, especially in acute and chronic forms.
Supporting Evidence
- The combination of AZT and IFN had a five-year overall survival of 46% for patients receiving first-line antiviral therapy.
- Patients with acute ATL had a significant survival advantage with first-line antiviral therapy compared to chemotherapy.
- Achievement of complete remission with antiviral therapy resulted in 82% five-year survival.
Takeaway
Doctors found that using two medicines together can help people with a type of blood cancer live longer, but they still need more help to get completely better.
Methodology
The study analyzed medical records of 254 ATL patients treated with zidovudine and interferon-alpha across various countries.
Potential Biases
Potential biases in patient selection and reporting of outcomes in small studies.
Limitations
Most patients eventually relapsed, indicating that the treatment does not cure ATL.
Participant Demographics
Patients included those with acute, chronic, and smoldering forms of ATL.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website